Physician profile
John P Cusack
NPI 1144298233
$7,091.32
in general payments reported to CMS, 2019-2025
53 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $314 · 2022: $238 · 2023: $1,248 · 2024: $1,683 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,040.19 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $827.91 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $803.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $770.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $761.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $300.76 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.35 | 2019-2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $191.12 | 2019-2023 | Qelbree |
| Allergan, INC. | $142.28 | 2019 | |
| Glaxosmithkline, LLC. | $110.87 | 2019-2025 | Trelegy Ellipta |
| Lundbeck LLC | $101.67 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $100.11 | 2019-2025 | Rexulti |
| Exact Sciences Corporation | $94.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $93.68 | 2023-2025 | |
| Amgen INC. | $93.37 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cusack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.